

BIOLIDICS LIMITED
(Company Registration No. 200913076M)
(Incorporated in the Republic of Singapore)

PROPOSED SUBSCRIPTION OF 98,500,000 NEW ORDINARY SHARES (THE “SUBSCRIPTION SHARES”) IN THE ISSUED SHARE CAPITAL OF BIOLIDICS LIMITED (THE “COMPANY”) BY MR. ZHU HUA (THE “PROPOSED SUBSCRIPTION”)

- ALLOTMENT AND ISSUANCE OF THE SUBSCRIPTION SHARES

The Board of Directors (the “**Board**”) of the Company refers to the Company’s announcements dated 21 November 2023 and 27 November 2023 in relation to the Proposed Subscription (“**Announcements**”). Unless otherwise defined, all capitalised terms used herein shall bear the same meanings as ascribed to them in the Announcements.

The Board wishes to announce that the Company has today, allotted and issued the 98,500,000 Subscription Shares to Mr. Zhu Hua. The Subscription Shares shall rank pari passu in all respects with the existing issued ordinary shares of the Company (“**Shares**”). The Subscription Shares are expected to be listed and quoted on Catalist on or about 30 November 2023.

Following the allotment and issuance of the Subscription Shares, the total number of Shares has increased from 559,126,605 to 657,626,605 Shares.

By Order of the Board

Song Tang Yih
Executive Director and Chief Executive Officer
28 November 2023

This announcement has been prepared by the Company and has been reviewed by the Sponsor for compliance with Rules 226(2)(b) and 753(2) of the Catalist Rules.

This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr. Lim Hoon Khiat, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.